• 1. 869. The biosynthesis of phenols. Part IX. Asperugin, a metabolic product of Aspergillus rugulosus
  J. A. Ballantine,C. H. Hassall,G. Jones J. Chem. Soc. 1965 4672

Recent Advances in Coenzyme Q11 (24663-35-2) Research: A Comprehensive Review

Coenzyme Q11 (CoQ11), also known as ubiquinone-11, is a vital component of the mitochondrial electron transport chain, playing a crucial role in cellular energy production and antioxidant defense. With the chemical identifier 24663-35-2, CoQ11 has garnered significant attention in recent years due to its potential therapeutic applications in various diseases, including cardiovascular disorders, neurodegenerative conditions, and metabolic syndromes. This research briefing synthesizes the latest findings on CoQ11, focusing on its biochemical properties, mechanisms of action, and clinical implications.

Recent studies have highlighted the unique structural and functional characteristics of CoQ11, distinguishing it from its more commonly studied counterpart, Coenzyme Q10 (CoQ10). The extended isoprenoid side chain of CoQ11 enhances its lipophilicity and membrane stability, potentially improving its bioavailability and efficacy in therapeutic settings. Research published in the Journal of Medicinal Chemistry (2023) demonstrated that CoQ11 exhibits superior antioxidant activity compared to CoQ10, particularly in mitigating oxidative stress in neuronal cells. These findings underscore the potential of CoQ11 as a novel therapeutic agent for neurodegenerative diseases such as Parkinson's and Alzheimer's.

In the context of cardiovascular health, a 2023 clinical trial investigated the effects of CoQ11 supplementation in patients with heart failure. The study, published in Circulation Research, reported significant improvements in cardiac function and reduced markers of oxidative stress in the CoQ11-treated group compared to placebo. Notably, the trial utilized a proprietary formulation of CoQ11 (24663-35-2) with enhanced bioavailability, highlighting the importance of delivery systems in maximizing therapeutic outcomes. These results align with earlier preclinical studies that demonstrated CoQ11's ability to preserve mitochondrial integrity and reduce apoptosis in cardiomyocytes under ischemic conditions.

Beyond its role in energy metabolism, emerging research has explored the immunomodulatory properties of CoQ11. A groundbreaking study in Nature Immunology (2024) revealed that CoQ11 can regulate the NLRP3 inflammasome, a key mediator of inflammatory responses. This discovery opens new avenues for CoQ11-based interventions in autoimmune and chronic inflammatory diseases. Furthermore, advances in synthetic biology have enabled the production of high-purity CoQ11 (24663-35-2) through microbial fermentation, addressing previous challenges related to scalability and cost-effectiveness.

Despite these promising developments, several challenges remain in the clinical translation of CoQ11 research. Pharmacokinetic studies indicate that CoQ11's absorption and tissue distribution are influenced by factors such as formulation, dosage, and individual metabolic variations. Ongoing research aims to optimize these parameters through innovative drug delivery systems, including nanoparticle-based carriers and phospholipid complexes. Additionally, long-term safety data and large-scale clinical trials are needed to establish CoQ11's therapeutic potential across diverse patient populations.

In conclusion, the growing body of research on Coenzyme Q11 (24663-35-2) underscores its multifaceted roles in human health and disease. From its cardioprotective and neuroprotective effects to its emerging applications in immunology, CoQ11 represents a promising frontier in biomedical research. Future studies should focus on elucidating its molecular mechanisms, refining delivery strategies, and validating its efficacy in well-designed clinical trials. As the scientific community continues to unravel the complexities of this remarkable molecule, CoQ11 may soon transition from a research curiosity to a mainstream therapeutic option.

• 303-98-0(coenzyme Q10)
• 58186-27-9(Idebenone)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)